Located in Tianhe District (North Campus) and Haizhu District (South Campus) of Guangzhou City, Fuda Cancer Hospital is under the jurisdiction of Health supervision bureau of Guangdong Province, a bureau that mostly regulates government founded hospitals. Fuda is an affiliated hospital to Jinan University and is the Translational Medicine Center of Guangzhou Institute of Biomedicine and Health of Chinese Academy of Sciences. Fuda operates under the international standards, and was selected as the National Key Clinical Speciality hospital (Oncology) in 2010. Fuda has several highly efficient and professional teams: cryosurgical ablation team, micro-vascular intervention team, immunotherapy team, surgical teams for head-neck, chest and a team for hepato-biliary cancer. The Joint Commission International (JCI), one of the most widely recognized hospital evaluation system, accredited Fuda Cancer Hospital in 2013. In Fuda, we value technology, integrity and humanity. Life is what we hold dear here. Fuda has been providing patients around the world with high-tech, world-class medical services. With all the miracles and success made in the past decade, Fuda is striving to reach the ultimate goal to become a hospital that is specialized in most novel cancer treatment, equipped with advanced medical instrument and focuses on cutting-edge oncological science. In the past decade, Fuda has been using latest cancer-treating technologies to treat patients who were in early or advanced stage of cancer. Fuda's treatment has helped patients by significantly prolonging patient’s survival time and improving life quality. Fuda has developed a unique “3C+P” treatment model, which is, cryosurgical ablation (CSA), CANCER MICRO-VASCULAR INTERVENTION (CMI), COMBINED IMMUNOTHERAPY FOR CANCER (CIC), AND PERSONALIZED TREATMENTS (P). So far, Fuda has had more than 10,000 cases of cryosurgical ablation, which ranks No.1 in the world in terms of quantity as well as the types of cancer treated. Fuda has attracted cancer patients from more than 70 countries around the world, 70 percent of patients from foreign countries in South-East Asia, the Middle East, Oceanic, Europe and North America. Fuda has received various awards in China and abroad for outstanding achievements in treating cancer and been highly praised by patients around the world.
